tbuckley/cabot-search huggingface dataset:
Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc
Authors: Sarah K. Madden, Aline Dantas de Araujo, Mara Gerhardt, David P. Fairlie, Jody M. Mason
Journal: Molecular Cancer (2021)

c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
Reply to Satoshi Funada, Takashi Yoshioka, and Yan Luo’s Letter to the Editor re: Ashley M. Hopkins, Ganessan Kichenadasse, Christos S. Karapetis, et al. Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab. Eur Urol 2020;78:540–3
Authors: Ashley M. Hopkins, Ganessan Kichenadasse, Michael J. Sorich
Journal: European Urology (2020)
Abstract 12877: Distinct Clinical Course by Type of Reverse Remodeling After Atrial Fibrillation Ablation in Patients With Left Ventricular Systolic Dysfunction
Authors: Masato Okada, Koichi Inoue, Koji Tanaka, Ohnishi Toshinari, Yuko Hirao, Takafumi Oka, Nobuaki Tanaka, Issei Yoshimoto, Ryo Kitagaki, Atsunori Okamura, Yasushi Koyama, Katsuomi Iwakura, Fujii Kenshi
Journal: Circulation (2019)

Introduction: Catheter ablation (CA) for atrial fibrillation (AF) is one of the effective treatments to achieve left atrial (LA) and left ventricular (LV) reverse remodeling (RR). The purpose of th...
15281 Effects of guselkumab on articular components of American College of Rheumatology score and skin responses in patients with active psoriatic arthritis: Results from the phase 3 DISCOVER-2 study
Authors: Alice B. Gottlieb, Philip J. Mease, Joseph F. Merola, Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Prasheen Agarwal, Désirée van der Heijde, Iain B. McInnes, Wolf-Henning Boehncke
Journal: Journal of the American Academy of Dermatology (2020)
SARS-CoV-2 RNAemia is associated with severe chronic underlying diseases but not with nasopharyngeal viral load
Authors: Judith Berastegui-Cabrera, Sonsoles Salto-Alejandre, Maricela Valerio, Patricia Pérez-Palacios, Francisco Arnaiz-De Las Revillas, Gabriela Abelenda-Alonso, José Antonio Oteo-Revuelta, Marta Carretero-Ledesma, Patricia Muñoz, Álvaro Pascual, Mónica Gozalo, Alexander Rombauts, Jorge Alba, Emilio García-Díaz, María Luisa Rodríguez-Ferrero, Adoración Valiente, María Carmen Fariñas, Jordi Carratalà, Sonia Santibáñez, Pedro Camacho-Martínez, Jerónimo Pachón, José Miguel Cisneros, Elisa Cordero, Javier Sánchez-Céspedes
Journal: Journal of Infection (2020)
Abstract 2605: Effect of Body Position on Heart Rate Recovery
Authors: John Canales, Anand Prasad, Todd Dorfman, Jeff Hastings, Qi Fu, Robin Shook, Dean Palmer, Benjamin Levine
Journal: Circulation (2006)

Background: Heart rate recovery (HRR) after dynamic exercise reflects the restoration of normal autonomic tone. Delayed HRR after clinical exercise testing has been associated with increased mortal...
Shiga toxin suppresses noncanonical inflammasome responses to cytosolic LPS
Authors: Morena S. Havira, Atri Ta, Puja Kumari, Chengliang Wang, Ashley J. Russo, Jianbin Ruan, Vijay A. Rathinam, Sivapriya Kailasan Vanaja
Journal: Science Immunology (2020)

Shiga toxin, a phage-encoded bacterial virulence factor, inhibits caspase-11–mediated inflammasome responses.
Handbuch der speziellen pathologischen Anatomie und Histologie.
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Resolution of Pulmonary Cement Embolism After Treatment of Rivaroxaban on Ventilation/Perfusion SPECT Image
Authors: Hae Won Kim, Hyun Jung Kim
Journal: Clinical Nuclear Medicine (2020)

A 73-year-old woman took a chest radiography for medical check-up, and pulmonary cement embolism was diagnosed. She had undergone percutaneous vertebroplasty. Ventilation-perfusion imaging revealed V/Q mismatched perfusion defect on the lung. Then, she has taken rivaroxaban (orally active direct factor Xa inhibitor) for 6 months and took follow-up V/Q scan. It revealed the disappearance of previous 2 of 3 moderate V/Q mismatches. There are controversies in the role of anticoagulation in treatment of pulmonary cement embolism, and this case shows functional recovery through the perfusion scan after anticoagulation treatment.
427P On the clinical implications of systemic and local immune responses in human angiosarcoma
Authors: J.Y. Chan, G.F. Tan, J. Yeong, C.W. Ong, D.Y.X. Ng, E. Lee, J. Koh, C.C.Y. Ng, J.Y. Lee, W. Liu, R.X. Wong, M. Farid, B.T. Teh
Journal: Annals of Oncology (2020)
Immunological mechanisms and therapeutic targets of fatty liver diseases
Authors: Hua Wang, Wajahat Mehal, Laura E. Nagy, Yaron Rotman
Journal: Cellular and Molecular Immunology (2020)

Abstract Alcoholic liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are the two major types of chronic liver disease worldwide. Inflammatory processes play key roles in the pathogeneses of fatty liver diseases, and continuous inflammation promotes the progression of alcoholic steatohepatitis (ASH) and nonalcoholic steatohepatitis (NASH). Although both ALD and NAFLD are closely related to inflammation, their respective developmental mechanisms differ to some extent. Here, we review the roles of multiple immunological mechanisms and therapeutic targets related to the inflammation associated with fatty liver diseases and the differences in the progression of ASH and NASH. Multiple cell types in the liver, including macrophages, neutrophils, other immune cell types and hepatocytes, are involved in fatty liver disease inflammation. In addition, microRNAs (miRNAs), extracellular vesicles (EVs), and complement also contribute to the inflammatory process, as does intertissue crosstalk between the liver and the intestine, adipose tissue, and the nervous system. We point out that inflammation also plays important roles in promoting liver repair and controlling bacterial infections. Understanding the complex regulatory process of disrupted homeostasis during the development of fatty liver diseases may lead to the development of improved targeted therapeutic intervention strategies.
Eosinophilic Esophagitis: Etiology and Therapy
Authors: Ronak V. Patel, Ikuo Hirano, Nirmala Gonsalves
Journal: Annual Review of Medicine (2020)

Eosinophilic esophagitis (EoE) is a relatively recently identified but now frequently encountered antigen/immune-mediated disease which places significant burden on patients and the healthcare system. With its growing prevalence and recognition by healthcare providers in multiple disciplines, substantial progress has been made regarding the diagnostic criteria, clinical evaluation, tools for disease assessment, and immune pathways related to pathogenesis. Current treatment goals focus on the amelioration of inflammation and prevention of remodeling consequences using proton pump inhibitors, swallowed topical steroids, elimination diets, and esophageal dilation. Ongoing research holds promise for more efficacious and targeted therapies as well as a personalized approach to the care of patients with EoE.
18583 Patient-centric approach to treatment of moderate to severe plaque psoriasis with secukinumab: Effectiveness and treatment persistence in the PURE registry
Authors: Kim Papp, Melinda Gooderham, Charles Lynde, Richard Langley, Vincent Ho, Mark Lomaga, Jennifer Beecker, Hermenio Lima, Antonio Vieira, Lenka Rihakova
Journal: Journal of the American Academy of Dermatology (2020)
Estimating the global economic benefits of physically active populations over 30 years (2020–2050)
Authors: Marco Hafner, Erez Yerushalmi, Martin Stepanek, William Phillips, Jack Pollard, Advait Deshpande, Michael Whitmore, Francois Millard, Shaun Subel, Christian van Stolk
Journal: British Journal of Sports Medicine (2020)

Objectives We assess the potential benefits of increased physical activity for the global economy for 23 countries and the rest of the world from 2020 to 2050. The main factors taken into account in the economic assessment are excess mortality and lower productivity. Methods This study links three methodologies. First, we estimate the association between physical inactivity and workplace productivity using multivariable regression models with proprietary data on 120 143 individuals in the UK and six Asian countries (Australia, Malaysia, Hong Kong, Thailand, Singapore and Sri Lanka). Second, we analyse the association between physical activity and mortality risk through a meta-regression analysis with data from 74 prior studies with global coverage. Finally, the estimated effects are combined in a computable general equilibrium macroeconomic model to project the economic benefits of physical activity over time. Results Doing at least 150 min of moderate-intensity physical activity per week, as per lower limit of the range recommended by the 2020 WHO guidelines, would lead to an increase in global gross domestic product (GDP) of 0.15%–0.24% per year by 2050, worth up to US$314–446 billion per year and US$6.0–8.6 trillion cumulatively over the 30-year projection horizon (in 2019 prices). The results vary by country due to differences in baseline levels of physical activity and GDP per capita. Conclusions Increasing physical activity in the population would lead to reduction in working-age mortality and morbidity and an increase in productivity, particularly through lower presenteeism, leading to substantial economic gains for the global economy.
Gender Compensation Gap for Ophthalmologists in the First Year of Clinical Practice
Authors: Jing Sasha Jia, Alexander Lazzaro, Alcina K. Lidder, Ceyhun Elgin, Jennifer Alcantara-Castillo, Steven J. Gedde, Albert S. Khouri, Aakriti Garg Shukla, Laurence T.D. Sperber, Janice C. Law, Yasha S. Modi, Eleanore T. Kim, Jeffrey R. SooHoo, Bryan J. Winn, Royce W. Chen, Lama A. Al-Aswad
Journal: Ophthalmology (2020)
368P Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study
Authors: H. Murakami, M. Tsuboi, H. Harada, T. Sobue, T. Kato, S. Atagi, T. Tokito, T. Mio, S. Oizumi, T. Kozuki, T. Sone, M. Seike, K. Ohashi, M. Jinushi, H. Horinouchi
Journal: Annals of Oncology (2020)
01. COMBINED BOSWELLIC ACID AND TEMOZOLOMIDE TREATMENT SELECTIVELY INDUCES APOPTOSIS AND REDUCES PROLIFERATIVE BEHAVIOUR IN GLIOBLASTOMA IN VITRO
Authors: Suzanne Birks, Melis Altinkaya, Ali Altinkaya, Geoff Pilkington
Journal: Neuro-Oncology (2012)

INTRODUCTION: Boswellia derivatives possess pro-apoptotic potential towards glioblastoma in vitro and inhibit cell growth. We investigated whether combining boswellic acid with either clomipramine or temozolomide has synergistic therapeutic potential and whether this would reduce viability of the ca
227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Authors: U.N. Vaishampayan, T. Elliott, A.G. Omlin, J.N. Graff, C.J. Hoimes, S.T. Tagawa, C. Hwang, D. Kilari, A.J. Ten Tije, R.S. McDermott, W.R. Gerritsen, H. Wu, J. Kim, C. Schloss, J.S. de Bono, E.S. Antonarakis
Journal: Annals of Oncology (2020)
Fecal Transplant for <i>Clostridioides difficile</i> Effective in Practice
Authors: Anita Slomski
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 19550: Chromosomal Microarray Abnormalities are Associated With Worse Prognosis in Infants With Prenatally Diagnosed Congenital Heart Disease
Authors: Erica Wu, Shabnam Peyvandi, Gary Satou, Laila Rhee Morris, Nina M Boe, Myriam Almeida-Jones, Deborah A Wing, Vanessa Wong, Tracy Anton, Maryam Tarsa, Delaram Molkara, Billie Lianoglou, Anita J Moon-Grady
Journal: Circulation (2017)

Introduction: Genetic abnormalities including common aneuploidies and copy number variants are known to influence both parental decisions regarding pregnancy and outcomes for infants with structura...
Engineering crops of the future: CRISPR approaches to develop climate-resilient and disease-resistant plants
Authors: Syed Shan-e-Ali Zaidi, Ahmed Mahas, Hervé Vanderschuren, Magdy M. Mahfouz
Journal: Genome biology (2020)

To meet increasing global food demand, breeders and scientists aim to improve the yield and quality of major food crops. Plant diseases threaten food security and are expected to increase because of climate change. CRISPR genome-editing technology opens new opportunities to engineer disease resistance traits. With precise genome engineering and transgene-free applications, CRISPR is expected to resolve the major challenges to crop improvement. Here, we discuss the latest developments in CRISPR technologies for engineering resistance to viruses, bacteria, fungi, and pests. We conclude by highlighting current concerns and gaps in technology, as well as outstanding questions for future research.
AB0491 ELEVATED COMPLEMENT 3 INDICATES DISEASE ACTIVITY IN TAKAYASU ARTERITIS
Authors: R. Chen, L. MA, S. Wu, L. MA, L. Jiang
Journal: Annals of the Rheumatic Diseases (2020)

Background: The disease activity evaluation of Takayasu arteritis (TA) is a critical issue for disease monitoring and treatment. But the previous markers such as Kerr score or ITAS 2010 are not convenient enough. Objectives: We aim to explore novel biomarkers to assess TA disease activity. Methods: This cross-sectional study was based on the East China TA (ECTA) cohort. Demographic characteristics, clinical features, laboratory and imaging results were collected. Complements and their combination with other biomarkers in identifying active disease (Kerr &gt;= 2) group were analyzed. Internal and external validation were employed to confirm the accuracy and stability of the results. Results: 519 patients were enrolled, among which 406 cases (72.2%) were identified as active disease. Higher ESR, CRP, platelet, globulin, IgG, IL-6, complement 3 (C3), complement 4 (C4) and median haemolytic complement (CH50) levels were observed in the active disease group. Logistic regression analysis demonstrated that C3 levels [odds ratio [OR] (95%CI): 10.710(1.825 – 62.835), P = 0.009] and CRP [OR (95%CI): 1.041(1.009 – 1.073), P = 0.011] were independently associated with active disease. The cut-off of C3 to identify active TA was 1.085 g/L, with 69.9% sensitivity, 66.7% specificity. Combining the CRP (cut-off, 10.65g/L; sensitivity, 50.7%; specificity, 82.4%) and C3, the sensitivity and specificity to identify the active disease were 85.1% and 55.0% (parallel test), and 35.4% and 94.1% (serial test), respectively. C3 could significantly improve the diagnostic ability of CRP [net reclassification index: OR (95%CI): 1.728 (1.556–1.990), P = 0.000; integrated discrimination index: OR (95%CI): 0.328 (0.224–0.431), P = 0.000]. The accuracy of the 10-fold cross validation of combining CRP with C3 was over 75%, and the accuracy of the external validation with 53 TA cases was 72.73%. Conclusion: C3 could reflect the disease activity of TA, and combining CRP with C3 could significantly improve the disease activity evaluation in TA. References: [1]Ma J, Luo X, Wu Q, Chen Z, Kou L, Wang H. Circulation levels of acute phase proteins in patients with Takayasu arteritis. J Vasc Surg. 2010;51(3):700-6. Acknowledgments: This work was supported by the National Natural Science Foundation of China [NSFC 81771730 and 81601398]. Disclosure of Interests: : None declared
Abstract IA40: Defining precursors in low-grade lymphomas that seed second lymphomas
Authors: Abner Louissaint, David Weinstock
Journal: Blood Cancer Discovery (2020)

Abstract Most patients with low-grade lymphoma will achieve a clinical remission (CR) with standard chemoimmunotherapy. Yet, relapse from minimal residual disease (MRD), either as low-grade or high-grade disease, remains the leading cause of death. Several studies have provided consistent evidence showing the strong prognostic value of measurable MRD using flow cytometry, PCR, next-generation sequencing, or other approaches. While MRD includes the malignant cells that remain in a patient who achieves CR, not all MRD cells may have the functional capability to proliferate into relapse. We recently introduced a nomenclature to more precisely distinguish cells included within MRD. In this nomenclature, M-REC (Minimal-RElapsable Cancer) denotes fully transformed cells capable of driving a relapse; MN-REC (Minimal Non-RElapsable Cancer) denotes fully-transformed cells incapable of driving a relapse; and MRP (Minimal Residual Precursors) denotes residual cells that harbor somatic and/or phenotypic alterations but are not fully malignant, such as those causing a dysplastic “field-effect” in cancers like those of the bladder, head and neck, or esophagus. Studies that defined the genetic phylogeny of lymphoma using diagnostic, relapsed, and transformed B-cell lymphomas from the same patients have identified examples where MRPs repeatedly evolve into clinical lymphomas. This conflicts with the traditional model of cancer evolution, in which “relapses” result from M-RECs that persist after therapy. There are two immediate implications to this paradigm-shifting concept: 1) Many “relapses” are actually second lymphomas, and 2) defining and targeting the vulnerabilities of MRPs may be essential for improving lymphoma-free survival among patients who achieve a CR. It is important to note that the vulnerabilities of MRD may differ within the bone marrow, blood, lymph node, and other sites, so sampling of each is essential. To make this possible, we have advanced two strategies. First, we have established xenografts of human follicular lymphoma explants within immunocompromised mice that capture both malignant and nonmalignant cellular components, as well as predictable transformation to large-cell lymphoma in vivo. Second, we have initiated rapid autopsies of patients with disseminated lymphoma to obtain specimens from multiple organs and thereby define the heterogeneity of environmental niches that support the persistence of MRD. Citation Format: Abner Louissaint, David Weinstock. Defining precursors in low-grade lymphomas that seed second lymphomas [abstract]. In: Proceedings of the AACR Virtual Meeting: Advances in Malignant Lymphoma; 2020 Aug 17-19. Philadelphia (PA): AACR; Blood Cancer Discov 2020;1(3_Suppl):Abstract nr IA40.
Endoscopic ultrasound-guided colonic anastomosis: pushing the boundaries
Authors: Sarah S. Al Ghamdi, Mouen A. Khashab
Journal: Endoscopy (2020)

Lumen-apposing metal stents (LAMS) have pushed the boundaries of interventional EUS beyond drainage of pancreatic fluid collections. EUS-guided gastroenterostomy (EUS-GE) using LAMS is now an accepted treatment modality for malignant gastric outlet obstruction (GOO) at many institutions. EUS-GE has multiple advantages over enteral stenting, including decreased risk of recurrent GOO due to stent occlusion. EUS-GE entails formation of an anastomosis between the stomach and a small bowel segment distal to the site of obstruction, usually the distal duodenum or proximal jejunum.
The nutrient sensing pathways FoxO1/3 and mTOR in the heart are coordinately regulated by central leptin through PPARβ/δ. Implications in cardiac remodeling
Authors: Blanca Rubio, Cristina Mora, Cristina Pintado, Lorena Mazuecos, Alejandro Fernández, Virginia López, Antonio Andrés, Nilda Gallardo
Journal: Metabolism (2020)
Atherosclerosis and Cell Cycle: Put the Brakes On!: Critical Role for Cyclin-Dependent Kinase Inhibitors⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: Rainer Wessely
Journal: Journal of the American College of Cardiology (2010)